Encyclopedia of Basal Cell Carcinoma Drugs_Novel and highly effective chemotherapy-targeted drugs from both domestic and international for Basal Cell Carcinoma patients

Current Location：Home>Basal Cell Carcinoma

Basal Cell Carcinoma

Odomzo

Specification：200mg*30Capsules

Manufacturer：

Price：$10494.00
Erivedge

Specification：150mg*28Capsules

Manufacturer：Novartis, Switzerland

Price：$2475.00

<<
<
1
>
>>
Jump to Page

Medication Guidance
Medication Q&A
Popular Drugs
New Drugs

FDA Approves 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer
Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development
Sacituzumab Govitecan Significantly Improves PFS Vs Chemo in HR+ Metastatic Breast Cancer
Frontline Poziotinib Produces Clinically Meaningful Efficacy in NSCLC Harboring HER2 Exon 20 Insertion Mutations
Tamoxifen Plus Extended Letrozole Improves DFS in Postmenopausal Breast Cancer
Ivosidenib/Azacitidine Granted Priority Review Designation by FDA for IDH1+ AML
Adjuvant Pembrolizumab Improves Distant Metastasis–Free Survival in Resected Stage IIB and IIC Melanoma
First-ever malaria vaccine recommendation now published in a position paper and in the WHO guidelines for malaria
Risk-Adaptive Approaches Offer Safer, Effective Strategies for Early-Stage HER2+ Breast Cancer
Employers Highlight Barriers to Biosimilar Adoption
Biomarkers Allow for Tailoring TNBC Treatments
These three risk factors may have the biggest impact on dementia cases